BioNTech’s Bold Bet: Navigating Financial Turmoil for a Revolutionary Cancer Breakthrough
BioNTech's Q4 2024 profit dropped, earning €1.08 per share from a previous €1.90, yet exceeded market expectations (€0.407). Revenue decreased to €1.19 billion from €1.479 billion, surpassing predictions (€1.093 billion).…